This finding was validated in more than 200 primary early-stage ovarian cancer tissues, with LGALS3BP being expressed in 43% of stage I/II tumors and 62% of stage III/IV tumors, indicating a positive association with tumor recurrence [47]. Here, LGALS3BP is linked to ovarian carcinoma.